[go: up one dir, main page]

MA28950B1 - Utilisation de cyclosporine dans le traitement d'infections a hepatite c et composition pharmaceutique contenant ladite cyclosporine - Google Patents

Utilisation de cyclosporine dans le traitement d'infections a hepatite c et composition pharmaceutique contenant ladite cyclosporine

Info

Publication number
MA28950B1
MA28950B1 MA29858A MA29858A MA28950B1 MA 28950 B1 MA28950 B1 MA 28950B1 MA 29858 A MA29858 A MA 29858A MA 29858 A MA29858 A MA 29858A MA 28950 B1 MA28950 B1 MA 28950B1
Authority
MA
Morocco
Prior art keywords
cyclosporine
treatment
hepatitis
infections
pharmaceutical composition
Prior art date
Application number
MA29858A
Other languages
English (en)
Inventor
Pietro Scalfaro
Jean-Maurice Dumont
Gregoire Vuagniaux
Rolland-Yves Mauvernay
Original Assignee
Debiopharm Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Debiopharm Sa filed Critical Debiopharm Sa
Publication of MA28950B1 publication Critical patent/MA28950B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C07K7/645—Cyclosporins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
MA29858A 2004-10-01 2007-04-27 Utilisation de cyclosporine dans le traitement d'infections a hepatite c et composition pharmaceutique contenant ladite cyclosporine MA28950B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IB2004003205 2004-10-01

Publications (1)

Publication Number Publication Date
MA28950B1 true MA28950B1 (fr) 2007-10-01

Family

ID=34959441

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29858A MA28950B1 (fr) 2004-10-01 2007-04-27 Utilisation de cyclosporine dans le traitement d'infections a hepatite c et composition pharmaceutique contenant ladite cyclosporine

Country Status (29)

Country Link
US (3) US7439227B2 (fr)
EP (1) EP1793844B1 (fr)
JP (1) JP4892486B2 (fr)
KR (1) KR101191833B1 (fr)
CN (1) CN101056648B (fr)
AT (1) ATE490778T1 (fr)
AU (1) AU2005290984B2 (fr)
BR (1) BRPI0515494A (fr)
CA (1) CA2580448C (fr)
CY (1) CY1114594T1 (fr)
DE (1) DE602005025232D1 (fr)
DK (1) DK1793844T3 (fr)
EA (1) EA012650B1 (fr)
ES (1) ES2357587T3 (fr)
GE (1) GEP20104960B (fr)
HR (1) HRP20110169T1 (fr)
IL (1) IL182362A0 (fr)
MA (1) MA28950B1 (fr)
MX (1) MX2007003387A (fr)
NZ (1) NZ554412A (fr)
PL (1) PL1793844T3 (fr)
PT (1) PT1793844E (fr)
RS (1) RS51614B (fr)
SG (1) SG139750A1 (fr)
SI (1) SI1793844T1 (fr)
TN (1) TNSN07084A1 (fr)
UA (1) UA88484C2 (fr)
WO (1) WO2006038088A1 (fr)
ZA (1) ZA200702610B (fr)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0320638D0 (en) 2003-09-03 2003-10-01 Novartis Ag Organic compounds
ATE497775T1 (de) 2004-07-14 2011-02-15 Novartis Pharma Gmbh Verwendung einer kombination von cyclosporin und pegylierten interferonen zur behandlung von hepatitis c (hcv)
US7196161B2 (en) 2004-10-01 2007-03-27 Scynexis Inc. 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis C infection
ES2314731T3 (es) 2004-11-22 2009-03-16 Astellas Pharma Inc. Analogo de ciclosporina.
CN101084005A (zh) * 2004-12-23 2007-12-05 诺瓦提斯公司 用于黄病毒科治疗的化合物
KR20070087624A (ko) 2004-12-23 2007-08-28 노파르티스 아게 Ｈｃｖ 치료용 조성물
CN101242842A (zh) * 2005-06-17 2008-08-13 诺瓦提斯公司 Sanglifehrin在hcv中的用途
DE602006020152D1 (de) 2005-09-30 2011-03-31 Scynexis Inc Arylalkyl- und heteroarylalkyl-derivate von cyclosporin a bei der behandlung und vorbeugung einer virusinfektion
KR20080059270A (ko) 2005-09-30 2008-06-26 싸이넥시스, 인크. Ｃ형 간염 감염의 치료 및 예방을 위한 방법 및 제약조성물
PT1957518E (pt) 2005-10-26 2016-02-26 Astellas Pharma Inc Novos compostos peptídicos cíclicos
KR101059593B1 (ko) 2006-04-11 2011-08-25 노파르티스 아게 Ｈｃｖ/ｈｉｖ 억제제 및 이들의 용도
CN101511357B (zh) 2006-05-19 2011-11-02 西尼克斯公司 环孢菌素类化合物及其组合物在制备治疗和预防眼部疾病的药物中的应用
BRPI0719189A2 (pt) * 2006-10-12 2018-08-14 Univ Kyushu Nat Univ Corp uso de ciclosporinas modificadas
WO2008069917A2 (fr) 2006-11-20 2008-06-12 Scynexis, Inc. Nouveaux peptides cycliques
KR20100017547A (ko) 2007-05-02 2010-02-16 아스텔라스세이야쿠 가부시키가이샤 신규 시클릭 펩티드 화합물
AU2008304313B2 (en) 2007-09-26 2013-01-10 Oregon Health & Science University Cyclic undecapeptides and derivatives as multiple sclerosis therapies
WO2009098533A1 (fr) * 2008-02-08 2009-08-13 Debiopharm Sa Cyclosporine non immunosuppressive pour le traitement de la dystrophie musculaire
US9090671B2 (en) 2008-06-06 2015-07-28 Scynexis, Inc. Macrocyclic peptides
US20090306033A1 (en) * 2008-06-06 2009-12-10 Keqiang Li Novel cyclic peptides
CN102202679B (zh) * 2008-11-06 2014-05-07 帝柏奥研究制药有限公司 环十一缩酚酸肽化合物及其作为药物的用途
CA2748389A1 (fr) 2008-12-31 2010-07-08 Scynexis, Inc. Derives de cyclosporine a
KR20110111321A (ko) 2009-01-30 2011-10-10 이난타 파마슈티칼스, 인코포레이티드 Ｃ형 간염을 예방하거나 치료하기 위한 사이클로스포린 유사체
US8481483B2 (en) 2009-02-19 2013-07-09 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
US20110182850A1 (en) 2009-04-10 2011-07-28 Trixi Brandl Organic compounds and their uses
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
US8349312B2 (en) 2009-07-09 2013-01-08 Enanta Pharmaceuticals, Inc. Proline substituted cyclosporin analogues
US8685917B2 (en) 2009-07-09 2014-04-01 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
US8367053B2 (en) 2009-07-09 2013-02-05 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
WO2011063076A1 (fr) 2009-11-19 2011-05-26 Itherx Pharmaceuticals, Inc. Méthodes de traitement du virus de l'hépatite c avec des composés d'oxo-acétamide
JP2013513595A (ja) 2009-12-09 2013-04-22 サイネクシス，インコーポレーテッド 新規環状ペプチド
US8623814B2 (en) 2010-02-23 2014-01-07 Enanta Pharmaceuticals, Inc. Antiviral agents
WO2011141891A1 (fr) 2010-05-12 2011-11-17 Debio Recherche Pharmaceutique S.A. Utilisation de composés cycloundécadepsipeptides
WO2012009715A2 (fr) 2010-07-16 2012-01-19 S&T Global Inc. Nouveaux dérivés de la cyclosporine destinés à traiter et à prévenir une infection virale
US9573978B2 (en) 2010-08-12 2017-02-21 S&T Global, Inc. Cyclosporin derivatives for the treatment and prevention of a viral infection
JP2013542206A (ja) * 2010-10-05 2013-11-21 ノバルティス アーゲー Ｃ型肝炎ウイルス感染症の新規治療
EA201390532A1 (ru) 2010-10-08 2013-09-30 Новартис Аг Композиции сульфамидых ингибиторов ns3, содержащие витамин е
WO2012072655A1 (fr) * 2010-11-30 2012-06-07 Novartis Ag Nouveaux traitements de l'infection par le virus de l'hépatite c
US9890198B2 (en) 2010-12-03 2018-02-13 S&T Global Inc. Cyclosporin derivatives and uses thereof
JO3337B1 (ar) * 2010-12-13 2019-03-13 Debiopharm Sa تركيبات صيدلية تشمل أليسبوريفير
RU2013148539A (ru) 2011-03-31 2015-05-10 Новартис Аг Алиспоривир для лечения инфекции вируса гепатита с
AU2012237295A1 (en) 2011-04-01 2013-09-19 Novartis Ag Treatment for infection with Hepatitis B virus alone or in combination with Hepatitis Delta virus and associated liver diseases
RU2013150344A (ru) * 2011-04-13 2015-05-20 Новартис Аг Лечение инфекции вируса гепатита алисповиром
BR112014007247A2 (pt) * 2011-09-27 2017-03-28 Novartis Ag alisporivir para o tratamento de infecção por vírus da hepatite c
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
PT107924A (pt) 2011-10-21 2014-12-03 Abbvie Inc Tratamento de combinação de daa (eg. com abt-072 ou abt-333) para utilização no tratamento de hcv
ES2572329B1 (es) 2011-10-21 2017-08-24 Abbvie Inc. Combinación de al menos dos agentes antivirales de acción directa y ribavirina pero no interferón, para uso en el tratamientodel vhc
WO2013169616A1 (fr) 2012-05-07 2013-11-14 Novartis Ag Modulation pharmacocinétique par de l'alisporivir
AR090964A1 (es) 2012-05-09 2014-12-17 Novartis Ag Proceso para la elaboracion de undecapeptidos ciclicos
WO2014085623A1 (fr) 2012-11-28 2014-06-05 Enanta Pharmaceuticals, Inc. Nouveaux analogues de [n-me-4-hydroxyleucine]-9-cyclosporine
US20140205566A1 (en) 2012-11-30 2014-07-24 Novartis Ag Cyclic nucleuoside derivatives and uses thereof
WO2015008223A1 (fr) 2013-07-17 2015-01-22 Novartis Ag Traitement du virus de l'hépatite c avec l'alisporivir et la ribavirine
RU2016110247A (ru) 2013-08-26 2017-10-02 Энанта Фармасьютикалс, Инк. Аналоги циклоспорина для предупреждения или лечения гепатита с
WO2015136455A1 (fr) 2014-03-13 2015-09-17 Novartis Ag Nouveaux traitements d'une infection par le virus de l'hépatite c
WO2016073480A1 (fr) 2014-11-03 2016-05-12 Enanta Pharmaceuticals, Inc. Analogues de cyclosporine pour prévenir ou traiter une infection par l'hépatite c
CA3022119A1 (fr) 2016-04-28 2017-11-02 Emory University Compositions therapeutiques a base de nucleotides et nucleosides contenant un alcyne et utilisations associees
KR102703402B1 (ko) 2017-05-12 2024-09-04 추가이 세이야쿠 가부시키가이샤 환상 유기 화합물의 제조 방법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2757522B1 (fr) * 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2757520B1 (fr) * 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Derive de cyclosporine, sa preparation et les compositions pharmaceutiques qui le contiennent
GB9811854D0 (en) * 1998-06-02 1998-07-29 Ciba Geigy Ag Organic compounds
AU759480B2 (en) * 1998-07-01 2003-04-17 Debiopharm S.A. Novel cyclosporin with improved activity profile
GB0320638D0 (en) * 2003-09-03 2003-10-01 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
EP1793844B1 (fr) 2010-12-08
CY1114594T1 (el) 2016-10-05
MX2007003387A (es) 2007-05-23
KR101191833B1 (ko) 2012-10-16
PT1793844E (pt) 2011-03-10
CN101056648A (zh) 2007-10-17
DE602005025232D1 (de) 2011-01-20
AU2005290984B2 (en) 2010-09-09
EA012650B1 (ru) 2009-12-30
RS51614B (sr) 2011-08-31
EA200700725A1 (ru) 2007-10-26
SG139750A1 (en) 2008-02-29
HRP20110169T1 (hr) 2011-04-30
US20090081164A1 (en) 2009-03-26
JP4892486B2 (ja) 2012-03-07
CN101056648B (zh) 2012-08-15
KR20070073761A (ko) 2007-07-10
ES2357587T3 (es) 2011-04-27
TNSN07084A1 (en) 2008-06-02
BRPI0515494A (pt) 2008-07-29
EP1793844A1 (fr) 2007-06-13
ZA200702610B (en) 2008-08-27
JP2008514690A (ja) 2008-05-08
NZ554412A (en) 2011-01-28
UA88484C2 (ru) 2009-10-26
GEP20104960B (en) 2010-04-26
USRE43371E1 (en) 2012-05-08
HK1104236A1 (en) 2008-01-11
DK1793844T3 (da) 2011-03-21
PL1793844T3 (pl) 2011-05-31
SI1793844T1 (sl) 2011-05-31
US20060252675A1 (en) 2006-11-09
AU2005290984A1 (en) 2006-04-13
CA2580448A1 (fr) 2006-04-13
CA2580448C (fr) 2012-09-18
ATE490778T1 (de) 2010-12-15
US7772184B2 (en) 2010-08-10
US7439227B2 (en) 2008-10-21
WO2006038088A1 (fr) 2006-04-13
IL182362A0 (en) 2007-07-24

Similar Documents

Publication Publication Date Title
MA28950B1 (fr) Utilisation de cyclosporine dans le traitement d'infections a hepatite c et composition pharmaceutique contenant ladite cyclosporine
DK1131065T3 (da) Diakyldumarater til behandling af autoimmunsygdomme
MA28740B1 (fr) Methodes de traitement d'infections endobronchiques
ATE314092T1 (de) Biologische kleber und verfahren zur topischen verabreichung von wirkstoffen
MA29273B1 (fr) Combinaison synergique de xolair/omalizumab/e25 et d'un agent immunosuppresseur
EP1689348A4 (fr) Composition d'oligosaccharides et leur utilisation dans le traitement d'infection
EA200200812A1 (ru) Фармацевтическая композиция, содержащая низкую дозу энтекавира, и ее применение
JP2007522237A5 (fr)
MA26317A1 (fr) Preparations combinees de derives de 1,1-dioxyde de 1,4-benzothiepine avec d'autres principes actifs et leur utilisation.
DZ3141A1 (fr) Inhibiteurs d'aminotransferase acides aminés-dépendante à chaîne ramifiée, et leur utilisation dans le cadre du traitement de la rétinopathie diabétique.
DK1228097T3 (da) Antimikrobiel aktivitet af den förste kationiske humane lactoferrin-klynge
NO2019032I1 (no) Treosulfan
MA30865B1 (fr) Utilisation de cyclosporines modifiees
FR2856599A1 (fr) Utilisation de compositions contenant une forme soluble d'hla-g dans le traitement de pathologies du sang.
BRPI0515588A (pt) uso de antagonistas de tgf-beta para limitar a nefrotoxicidade de agentes imunossupressivos
CA2306441A1 (fr) Peptides issus de gene env du virus de l'immunodeficience feline et leurs applications
MA27474A1 (fr) Vaccin
FR2806911B1 (fr) Utilisation de mimetiques de la sod dans le traitement d'insuffisances hepatocellulaires
DE602004011843D1 (de) Die myocardfunktion wiederherstellende peptidsubstanz
CY1109316T1 (el) Συνδυαστικη αγωγη για πολλαπλη σκληρυνση
CU20070072A7 (es) Uso de [d-meala]3-[etval]4-ciclosporina para el tratamiento de infección por hepatitis c y composición farmacéutica que comprende la [d-meala]3-[etval]4-ciclosporina